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Interaction between 132.microglobulin and advanced glycation end
products in the development of dialysis related-amyloidosis. Dialysis
related amyloidosis (DRA) is a progressive debilitating complication of
long-term dialysis. 32-microglobulin (132m) amyloid deposition occurs
preferentially in older patients and initially is located in collagen-rich
osteo-articular tissues. Since an age-dependent increase in the formation
of advanced glycation end products (AGE) has been observed in collagen-
containing structures, we hypothesized that AGE-modified f32m in the
amyloid of DRA may be formed locally in osteo-articular structures as a
subsequent event of its binding to collagen-AGE. Based on this hypoth-
esis, we investigated the binding between f32m and AGE-modified collagen
(collagen-AGE) in vitro. Significantly larger amounts of human 32m were
bound to types Ito IV of immobilized collagen-AGE than to unmodified
collagens (P < 0.0001). The quantity of f32m bound to collagen-AGE was
dependent on the concentrations of both f32m and of AGE contained in
collagen (P < 0.01). Unmodified 2m was more avidly bound to collagen-
AGE or collagen in comparison to AGE-modified j32m (P < 0.000 1). j32m
bound to collagen-AGE could be modified further by nonenzymatic
glycosylation during three weeks of incubation with physiologic concen-
trations of glucose. Similar processes in vivo may be important in the
pathobiology of DRA.
Dialysis-related amyloidosis (DRA) is a serious, often incapac-
itating complication for older patients undergoing long-term
dialysis [1—3]. Initially, amyloid deposits are mainly located in
osteo-articular tissue, leading to carpal tunnel syndrome, destruc-
tive arthropathy, and subchondral bone erosions and cysts [4—61.
Later in the course of the disease, deposition extends to the
viscera and vasculature [TI. Recent biochemical and immunohis-
tological studies have demonstrated that p2-microglobulin (132m)
is a major constituent of the amyloid fibrils in DRA [8, 91. 2m, a
protein with a molecular weight of 11800 daltons, is produced by
all nucleated cells and is normally eliminated by the kidney [10].
Thus, the [32m level is markedly elevated in persons with chronic
renal failure as compared with healthy individuals [10]. However,
no correlation between the serum or joint concentrations of g!32m
and the occurrence of DRA has been observed [11]. Furthermore,
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little is known about the mechanism for the preferential recruit-
ment of 132m to osteo-articular structures.
Clinical observations have shown that the incidence and prev-
alence of DRA increase with age [2, 31. Osteo-articular tissue,
which is rich in collagen, is the most common site of deposition of
/32m amyloid [1]. With advancing age, a linear increase in ad-
vanced glycation end product (AGE) accumulation in collagen
has been demonstrated [12]. Therefore, we hypothesized that
there is an affinity between /32m and AGE-modified collagen that
might promote the preferential accumulation of 132m amyloid
deposits in older persons with chronic renal failure.
Methods
Preparation of AGE-modified proteins
AGE-modified f32m and collagens were prepared in vitro as
previously described [13]. Briefly, 1.75 mg/mI of purified normal
human f32m (Cortex Biochem, San Leandro, CA, USA) or 0.45
mg/ml of purified type I (from calf skin; Sigma, St. Louis, MO,
USA), type II (from bovine trachael cartilage; Sigma), type III
(from human placenta; Sigma), and type IV (from human pla-
centa; Sigma) collagen were incubated separately at 37°C for 30
days with 100 mt D-glucose in 100 m phosphate buffer contain-
ing 200 U/ml penicillin, 70 j.tg/ml gentamicin, and 1.5 mtvi PMSF.
Samples incubated in an identical manner in the absence of
glucose were used as controls. For some experiments, unincu-
bated 132m or collagen were used as additional controls. After
incubation, all samples were dialyzed against phosphate buffer
(pH 7.4) and lyophilized.
Characterization of AGE-modified proteins
AGE-modified proteins were characterized by solid phase
enzyme-linked immunosorbent assay (ELISA) and fluorospec-
trometry. An ELISA was performed as described by using the
ELISA Starter Kit (Pierce, Rockford, IL, USA) [14]. In brief,
AGE-modified proteins and control samples at various concen-
trations (0.001 to 20 JLg/ml) were immobilized on 96-well polysty-
rene plates by incubation for 12 hours at 4°C. Each well was
washed three times and nonspecific binding sites were blocked
with blocking buffer composed of 1% bovine serum albumin
(BSA). A polyclonal rabbit antiserum raised against KLH-AGE
(gift of Dr. John Baynes, University of South Carolina) was
reacted with the immobilized proteins at 1:2500 for one hour at
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room temperature. A previous study had demonstrated that
anti-AGE antibody specifically recognized various AGE proteins,
but not early products such as Schiff bases and Amadori products
[151. The wells were then washed with buffer, incubated with 100
jil of goat anti-rabbit lgG-peroxidase (dilution of 1:5000) (Pierce)
followed by addition of the substrate 2,2'-azino-di-3-ethylbenz-
thiazoline-6-sulfonic acid (ABTS). The absorbance at 405 nm was
measured on a micro-ELISA plate reader (Titertek Multiskan,
Mcc/340).
The fluorescence spectra of the AGE-modified proteins and the
control samples were measured at a protein concentration of 0.26
mg/mI in a fluorescence spectrophotometer (Aminco Bowman
Series 2) The maximum emission fluorescence intensities at 430
nm were determined upon excitation at 360 nm [161.
Binding assays
All buffers and substrate were obtained from an ELISA Starter
Kit as described above. Type I collagen incubated with or without
glucose and unincubated type I collagen were dissolved in 0.05 N
acetic acid, and each solution was adjusted to 10 tg/ml using the
coating buffer provided in the kit. Individual collagen solutions
(100 .Ll) were placed in 96-well polystyrene microplates and
incubated for 12 hours at 4°C in a moist chamber. The solution
was discharged, and the wells were rinsed three times with 100 jd
of wash buffer. Blocking buffer (100 tl) was added and allowed to
incubate for one hour. After emptying the plates, aliquots (100 d)
of j32m (25 to 100 g/ml) incubated with or without glucose, and
unincubated f32m, were added to the wells and incubated for one
hour at room temperature. After washing three times with wash
buffer, 100 j.tl of affinity purified sheep anti-human 2m antibody
(dilution of 1:2500; BiosPacific Inc., Emeryville, CA, USA) was
added, and the incubation was allowed to proceed at room
temperature for 60 minutes. Each well was rinsed three times, and
100 d of rabbit anti-sheep IgG-peroxidase (dilution of 1:5000;
Pierce) was added. After incubation at room temperature for 60
minutes, the wells were washed, and 100 pi of ABTS was added to
each well. The reaction proceeded at room temperature for an
additional 30 minutes. The absorbance at 405 nm was measured
by using an ELISA reader as described above. Control studies
were performed using collagen-coated plates incubated with
blocking buffer alone or plates initially incubated with coating
buffer without collagen.
To test the interaction between the amount of AGE in collagen
and its binding capacity for 2m, type I collagen-AGE and
unincubated type I collagen were mixed at various ratios. The
mixed collagen solution was then used at concentration of 10
g/ml to coat the plate, and the plate was incubated with fresh
132m (75 jtg/ml).
To determine the relative specificity of binding of 2m to
collagen-AGE or unmodified collagen, two group of experiments
were performed. In the first group, plates were individually coated
with AGE-modified type I, II, III and IV collagens or their
unmodified forms, and the coated plates were incubated with 75
g/ml of /32m. In the second group, type I collagen-AGE or its
unmodified form were immobilized onto the plates and incubated
with 2m, human serum albumin (HSA, Sigma) and human IgG
(HIgG, Pierce) at identical concentrations (75 J.Lg/ml). The bind-
ing was determined by reaction with sheep anti-/32m (dilution of
1:2500), sheep anti-HSA (dilution of 1:2500; Boehringer Mann-
heim, Indianapolis, IN, USA) and sheep anti-HIgG (dilution of
1:2500; Boehringer Mannheim), respectively.
Nonenzymatic glycosylation of j32in bound to collagen
Under sterile conditions, all solutions were filtered through a
0.22 jsm pore filter (Sarstedt, Newton, NC, USA). Type I
collagen-AGE and unincubated type I collagen were coated Onto
96-well microplates for 12 hours as described above. The wells
were rinsed three times. Sixteen microliters of 2m solution (final
protein concentration 75 tg/ml) were then added and incubated
separately at 37°C for three weeks with 100 .d of D-glucose
solution (final concentration of glucose 0 to 100 m in 100 mM
phosphate buffer) containing 200 U/ml penicillin, 70 tg/ml gen-
tamicin and 1.5 ms'i PMSF. The incubation solution was changed
eveiy seven days by aspiration of the solution and replacement
with fresh incubation solution containing the original concentra-
tion of f32m and glucose. At the end of the incubation period, the
wells were rinsed three times with wash buffer. One hundred
microliters of rabbit anti-KLH-AGE (1:2500) antibody was added
prior to incubation at room temperature for one hour. Each well
was rinsed three times, and 100 jil of goat-anti rabbit IgG-
peroxidase (dilution of 1:5000) was added. After incubation at
room temperature for one hour, the wells were washed, and
reacted with 100 d of ABTS at room temperature for 30 minutes.
The absorbance at 405 nm was then measured by using an ELISA
reader as described above. Control studies were performed using
rabbit anti-human IgG (dilution of 1:2500; Boehringer Mann-
heim) and sheep anti-human f32m (dilution of 1:2500; Boehringer
Mannheim) instead of rabbit anti-KLH-AGE antibody.
Statistical analyses
All experiments were performed in triplicate. Continuous vari-
ables, expressed as mean SD, were compared using analysis of
variance (ANOVA). The Student-Newman-Keuls procedure was
used to evaluate pairwise comparisons. Two-tailed P values < 0.05
were considered statistically significant. Statistial analyses were
conducted with SAS (The SAS Institute, Cary, NC, USA).
Results
Formation of AGE modified proteins
After incubation for 30 days with 100 m glucose, j32m and the
four collagens individually reacted with anti-AGE antibody. Par-
allel incubations of 2m or collagens without glucose, or the fresh
proteins, were without immunoreactivity. Comparison of AGE
formation between the four types of collagen showed that the
immunoreactivity of the type IV collagen product was significantly
weaker than that from the other three types of collagen (Fig. 1)
The reaction of the proteins with the anti-AGE antibody did not
reflect nonspecific binding, because the glycosylated proteins did
not react with anti-human Ig (data not shown). These data suggest
that 132m-AGE and collagen-AGE were formed during the pro-
tein incubations with glucose.
The modification of 2m and collagens to AGE was further
supported by their typical fluorescence spectra. 2m and collagens
incubated with glucose showed intense fluorescence, with a major
excitation maximum at 360 nm for emission at 430 nm and a major
emission maximum at 430 nm upon excitation at 360 nm. In
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Fig. 1. The presence of AGE formation in coliagens incubated with D-
glucose. Microplates coated with 20 pg/mI of types I, IT, III and IV
collagen incubated with 100 mi D-glucose for 30 days were reacted with
anti-AGE antibody. Data from three independent experiments are ex-
pressed as mean so. ANOVA, P < 0.01. The immunoreactivity of type
IV collagen differs significantly from types 1, 11 and III.
contrast, control samples incubated without glucose and unincu-
bated proteins did not fluoresce. In two experiments, after adjust-
ing for the quantity of protein, AGE formation was 17% and 23%
less from type IV than from type I.
Binding specificity of (32m to collagen-AGE
Microplates were coated with type I collagen-AGE and incu-
bated with f2m or j32m-AGE. /32m readily bound to immobilized
type I collagen-AGE. The quantity of f32m bound was significantly
higher than that of AGE modified 2m (Fig. 2A; P < 0.0001).
There was no significant difference in quantity bound of unincu-
bated 132m compared with that incubated without glucose. At all
concentrations of 132m, the quantity bound to type I collagen-
AGE was significantly greater than to unmodified collagen (col-
lagen-control) or fresh collagen (Fig. 2B; P < 0.0001).
Further support for the relative binding specificity of 132m for
collagen-AGE was provided by mixing experiments in which
plates were coated with incremental ratios of type I collagen-AGE
and unincubated collagen (fixed final concentration of 10 j.rg!ml),
to which a solution of 75 jrg/ml of f3m was subsequently added.
For ratios of 0, 0.25, 0.5, and 1.0 (collagen-AGE:unincubated
collagen), absorbances of 0.57 0.02, 0.83 0,09, 0.99 0.02,
and 1.20 0,02 were observed (P < 0.0001). Regression analysis
showed a direct correlation between the ratio of collagen-AGE
and the quantity of /32m hound (r = 0.97, P < 0.0001).
/32m was equally bound to all four types of collagen-AGE, as
well as to the four types of unmodified collagen. Compared with
/32m and HSA, HIgG bound less well to collagen and collagen-
AGE. The same pattern of increased binding to collagen-AGE
relative to unmodified collagen was observed for all of these
plasma proteins (Fig. 3).
Nonenzymatic glyco3ylation of collagen-bound 132m
Microplates coated with collagen-AGE or collagen were incu-
bated for three weeks with incremental glucose concentration in
-,_/r
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Fig. 2. A. Binding of /32m and /321n-AGE to collagen-AGE. Microplates
coated with 10 /Lg/ml of type I collagen-AGE were incubated with /32m
(0), f32m incubated without D-glucose (•), and 132m-AGE (A). Bound
132m was quantitated by ELISA using anti-132m antibody. Each point was
derived from three independent experiments. (ANOVA, P < 0.0001; A
differs significantly from 0 and •). B. Binding of 132m to collagen-AGE
and collagen. Microplates coated with 10 pg/mI of type I collagen-AGE
(0), type I collagen incubated without D-glucose (•) and fresh type I
collagen (A) were incubated with 132m. Bound 132m was quantitated by
ELISA using anti-f32m antibody. Results from three independent experi-
ments were expressed as mean so. (AMOVA, P < 0.0001; collagen type,
P < 0.0001; 2m concentration, P = 0.0005; 0 differs significantly from •
and A).
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the presence or absence of 2m (75 .tg/ml). After incubation with
7m, both collagen-AGE and collagen coated plates reacted with
the anti-/32m antibody, suggesting that 132m had bound to both
immobilized collagen-AGE and unmodified collagen. No reaction
was detected when the plates were incubated without 132m.
Nonenzymatic protein glycosylation was detected by ELISA using
the anti-AGE antibody. In the presence and absence of /32m,
increased glucose concentrations were associated with increased
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Fig. 3. Binding of selected proteins to collagen and collagen-AGE. Micro-
plates coated with type I collagen (•) or type I collagen-AGE (i1) at a
concentration of 10 rg/ml were incubated with 132m, HSA, and HIgG (75
g/ml for each protein). Bound proteins were determined by ELISA using
anti-132n1, anti-HSA and anti-HIgG antibodies, respectively. Data from
three independent experiments were expressed as mean SD. (ANOVA,
I' < 0.0001; protein type, P < 0.0001; collagen nonenzymatic glycation
status, P < 0.0001; protein X collagen nonenzymatic glycation status
interaction, P = 0.01. HIgG differs significantly from HSA and 132m).
immunoreactivity. Moreover, for any glucose concentration, the
immunoreactivity was greater for wells incubated with /32m. This
suggests that f32m bound to collagen-AGE underwent AGE
formation in situ (Fig. 4A). In control experiments (Fig. 4B),
collagen-coated plates were incubated with incremental glucose
concentrations in the presence or absence of /32m (75 jig/mI).
Under these conditions, there was no significant difference in
AGE-protein formation with and without /32m.
The affinity of f32m for other substances including native
collagens has been previously reported [17—19]. Spiegel and
co-workers have also observed that 132m is found associated with
collagen in the dermis of patients on dialysis [20]. Our results
demonstrated that 132m can bind to AGE-modified collagens in
vitro, and the amount bound was significantly higher than to
unmodified collagens. The quantity of f32m bound was dependent
on the concentration of either f32m or AGE-modified collagen.
Although we cannot exclude the possibility that the parallel
accumulation of 132m and collagen-AGE in older dialysis patients
may be fortuitous, the findings of a significant physical interaction
between these proteins suggest an alternative pathobiologic ex-
planation for the age-dependent occurrence of DRA. Retention
of /32m due to chronic renal failure could be a prerequisite for the
accumulation of 132m amyloid, while the increased amount of
AGE in collagen seen with advanced age may be an important
provocative factor in the occurrence of DRA.
We observed that 2m can interact with various types of
collagen-AGE. However, AGE formation in type IV collagen was
reduced compared with types I, II and III under identical incu-
bation conditions. Unlike type I, II and III collagens (class 1
collagens), type IV collagen is a member of the class 3 collagen
group. The structure, function, and distribution of the collagens in
this class differ substantially from those in class 1. Class 1 collagen
forms the banded collagen fibers that are the major interstitial
collagen present in cartilage, skin, tendon, ligament, bone and
other connective tissues. They contain three alpha chains and are
first synthesized as procollagen. Class 3 collagen forms indepen-
dent fiber systems that include basement membranes and beaded
filaments. Type IV collagen contains two alpha chains with a
complex globular domain at the carboxyl terminus. Carbohydrate
accounts for 10% of the mass of type IV collagen, a higher level
than is found in most other collagens [21]. The relationship
between the structures of the collagen classes and their relative
ability to form AGEs is unknown.
However, the relative ease of formation of class I collagen-
AGE may account for the observation that early in the course of
DRA, amyloid deposits are localized predominantly in joints and
periarticular bone. These structures are rich in class I collagen.
Later in the progression of DRA, amyloid deposition occurs in
basement membrane containing structures, such as the vascula-
ture and gastrointestinal tract, that contain type IV collagen as a
major component [7].
The close proximity of AGE-modified proteins with matrix
proteins such as collagen has been previously emphasized [22, 23].
Other plasma proteins such as HSA and HIgG can also bind to
collagen-AGE in vitro, suggesting that the binding of 2m to
collagen-AGE in vivo may not be specific. Because immunohisto-
logical studies have demonstrated that f32m is a major constituent
of the amyloid fibrils in DRA [16], factors other than simple
binding and local accumulation of /32m to collagen-AGE must be
involved. It has been suggested that f32m amyloid is selectively
resistant to degradation, which may account for the relative
homogeneity of the deposits [24—26].
While the increase in circulating AGE-modified proteins ob-
served in diabetes is due to an increase in AGE production, it
appears to be due to decreased clearance in chronic renal failure
[27]. Makita et al showed that the serum AGE level of small-
molecular weight proteins was increased among non-diabetic
patients undergoing hemodialysis [27]. Furthermore, it has been
demonstrated that f32m in the amyloid deposits in DRA is
modified by AGE [16]. Thus, it has been hypothesized that the
increased circulating serum concentrations of f32m undergo gly-
cosylation into AGE with time, and f32m-AGE ultimately deposits
to form f32m amyloid in collagen-rich tissues [28]. We found that
native f32m, but not j32m-AGE, had a relatively higher affinity for
collagen-AGE or unmodified collagen. This suggests another
possibility. 132m may be initially bound to collagen-AGE or
collagen and modified locally to AGE as a subsequent event. The
demonstration that infusion of radiolabeled f32m rapidly localizes
to osteoarticular structures supports this hypothesis [29, 30]. Once
unmodified, short-lived plasma proteins become attached to
matrix proteins, their continuous accumulation in the tissue may
provide adequate time for these recruited proteins to form AGEs
[121.
To explore these hypotheses, we conducted experiments to
determine whether 2m could be modified to AGE when it was
bound to collagen-AGE. The nonenzymatic glycosylation of f32m
increased with higher glucose concentrations. Because the same
concentration of f32m had no effect on nonenzymatic glycosylation
in plates coated with unmodified collagen, this increased AGE-
formation could not be attributed to the promotive effect of j32m
on the AGE formation occurring in collagen. Therefore, we
B Fig. 4. AGE formation of j132m bound to
collagen. Microplates coated with type I
collagen-AGE (A) or unincubated type I
collagen (B) were incubated with D-glucose in
the absence (•) or in the presence (0) of 132m
(75 jsg/ml) for three weeks. AGE formation
was assessed by ELISA using anti-AGE
antibody. Data from three independent
experiments were expressed as mean SD.
ANOVA, P < 0.0001; collagen nonenzymatic
glycation status, P < 0.0001; with or without
2m, P < 0.0001; glucose concentration, P <
0 6 25 25 50 75 100 0.0001; /32m X collagen nonenzymatic glycationstatus interaction, P = 0.007; collagen
nonenzymatic glycation status X glucose
concentration interaction, P 0.03.
High plasma and synovial fluid levels of
2m due to decreased GFR
Age-dependent increase
of AGE in collagen
2m binds to collagen-AGE (class 1 > class 3)
with preferential accumulation in oste-articular
structures
2m modified in situ to 32m-AGE
1
Enhanced accumulation of 32m
and other proteins through cross-
linking
2m amyloid formation
suggest that the increased AGE-formation after incubation of
(3,m with collagen-AGE reflects the AGE modification of bound
/32m.
No clinical correlation has been reported between DRA and
diabetes mellitus [31]. Of particular clinical interest is the obser-
vation that /32m bound to collagen-AGE was modified to AGE in
the presence of physiologic concentrations of glucose. This may
explain the clinical phenomenon of DRA in patients with non-
diabetic chronic renal failure [21. In addition, blood deoxyglucose
levels arc quite elevated in non-diabetic ESRD patient, and
deoxyglucose may be a contributing carbohydrate facilitating
2m-AGE formation in non-diabetic dialysis patients [321. The
absence of literature reporting diabetes mellitus as a risk factor
for DRA is not surprising. ESRD patients with diabetes may not
survive sufficiently long to develop DRA, that is, competing risks.
The five-year death rate for diabetics with ESRD is twice that for
Fig. 5. Proposed recruitment mechanism for fl-jo
amyloid deposition in DRA.
nondiabetes (20% vs. 39% surviving, respectively) [33]. Further-
more, if deoxyglucose is a major provocateur for /32m-AGE
formation in vivo, the elevated blood levels in diabetics and
non-diabetics would render both groups at equal risk for devel-
oping DRA.
Based on these results, the following mechanism is proposed
(Fig. 5): 2m initially and preferentially accumulates in osteo-
articular tissue through binding to class 1 collagen-AGE, and then
undergoes AGE modification. The new end product on this
incorporated protein may then serve as an attachment site for
additional f32m or other plasma proteins and eventually form
amyloid fibrils.
In conclusion, we demonstrate that /32m binds to AGE modified
collagens, and this incorporated f32m can be modified further to
AGEs. This may prove to be a potential recruitment mechanism
in the pathogenesis of DRA.
A
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